Clarity Pharmaceuticals Ltd has released a press release.
FDA Fast Track Designation 64CU-SAR-bisPSMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Supply agreement for Ac-225 with TerraPower Isotopes
- Clarity strengthens Cu-64 network with new supply agreement
- Complete response with Cu-67 SAR-bisPSMA
- Successful Completion of Retail Entitlement Offer
- Despatch of Retail Entitlement Offer Booklet
Later from Clarity Pharmaceuticals
- S&P DJI Announces September 2024 Quarterly Rebalance
- SECuRE trial advances
- Shareholder briefing - presentation
- Michelle Parker Promoted to CEO
- Positive guidance from the US FDA on Phase III trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals